 |
|
|
|
|
Publications
Potency of dendritic cell based immunotherapies is correlated with IL-12 production by tracking the induction of multi-functional CD8+/CD28+ cytotoxic T cell immunity
MA DeBenedette, DM Calderhead, IY Tcherepanova, CA Nicolette, DG Healey. J Immunother. 2011 Jan;34(1):45-57.
Prevention of chronic renal allograft rejection by soluble CD83.
Lan Z, Lian D, Liu W, Arp J, Charlton B, Ge W, Brand S, Healey D, DeBenedette M, Nicolette C, Garcia B, Wang H.
Transplantation. 2010 Dec 27;90(12):1278-85.
Induction of kidney allograft tolerance by soluble CD83 associated with prevalence of tolerogenic dendritic cells and indoleamine 2,3-dioxygenase.
Lan Z, Ge W, Arp J, Jiang J, Liu W, Gordon D, Healey D, DeBenedette M, Nicolette C, Garcia B, Wang H
Transplantation. 2010 Dec 27;90(12):1286-93.
Immunosuppression involving soluble CD83 induces tolerogenic dendritic cells that prevent cardiac allograft rejection.
Ge W, Arp J, Lian D, Liu W, Baroja ML, Jiang J, Ramcharran S, Eldeen FZ, Zinser E, Steinkasserer A, Chou P, Brand S, Nicolette C, Garcia B, Wang H.
Transplantation. 2010 Dec 15;90(11):1145-56.
Structural identification of recombinant human CD83 mutant variant as a potent therapeutic protein.
Zhang L, Narayanan N, Brand SR, Nicolette CA, Baroja M, Arp J, Wang H, Moo-Young M, Chou CP.
Protein Expr Purif. 2010 Oct;73(2):140-6. Epub 2010 Jun 8.
Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection
Routy JP, Nicolette C. Immunotherapy. 2010 Jul;2(4):467-76.
A Short Pulse of IL-4 Delivered by DCs Electroporated With Modified mRNA Can Both Prevent and Treat Autoimmune Diabetes in NOD Mice.
RJ Creusot, P Chang, DG Healey, IY Tcherepanova, CA Nicolette and CG Fathman. Molecular Therapy (2010); doi:10.1038/mt.2010.146
Bioprocess development for production, purification, and structural characterization of recombinant hCD83ext as a potential therapeutic protein.
Xu Y, Zhang L, Yao W, Yedahalli SS, Brand S, Moo-Young M, Perry Chou C. Protein Expression and Purification, In Press
Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.
Routy J, Boulassel M, Yassine-Diab Y, Nicolette C, Healey D, Jain R, Landry C, Yegorov O, Tcherepanova I, Monesmith T, Finke L and Sekaly R. Clin. Immunol., 134, 140-147 (2010).
Combination immunosuppression involving sCD83 induces adoptively transferable tolerogenic DCs that can prevent cardiac allograft rejection.
Wei Ge, Jacqueline Arp, Dameng Lian, Weihua Liu, Miren L. Baroja, Siobhan Ramcharran, Firas Zahr ElDeen, Elisabeth Zinser, Alex Steinkasserer, Perry Chou, Stephen Brand, Charles Nicolette, Bertha Garcia, Hao Wang, 2009 (Submitted)
Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection.
Tcherepanova I, Harris J, Starr A, Cleveland J, Ketteringham H, David Calderhead, Joe Horvatinovich, Don Healey, Charles A Nicolette. PLoS ONE 3(1): e1489. doi:10.1371/journal.pone.0001489 2008
Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion.
Irina Y Tcherepanova, Melissa D Adams, Xiaorong Feng, Atsushi Hinohara, Joe Horvatinovich, David Calderhead, Don Healey and Charles A Nicolette. BMC Molecular Biology 2008, 9:90 doi:10.1186/1471-2199-9-90
Priming of a novel subset of CD28: rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells Is IL-12 dependent.
Mark A. DeBenedette, David M. Calderhead, Helen Ketteringham, Alicia H. Gamble, Joe M. Horvatinovich, Irina Y. Tcherepanova, Charles A. Nicolette, and Don G. Healey. The Journal of Immunology, 2008, 181: 5296–5305.
Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response.
David M. Calderhead, Mark A. DeBenedette, Helen Ketteringham, Alicia H. Gamble, Joe M. Horvatinovich, Irina Y. Tcherepanova, Charles A. Nicolette, and Don G. Healey. J Immunother 2008; 31:731–741
Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products.
Nicolette C, Healey D., Tcherepanova I., Whelton P., Monesmith T., Coombs L., Finke L., Whiteside T., and Miesowicz F. Vaccine V 25, 2007 pp B48-B60
An improved RNA amplification procedure results in increased yield of autologous RNA transfected dendritic cell-based vaccine.
Jason Harris, Tamara Monesmith, Alicia Ubben, Marcus Norris, Jonathan H Freedman, Irina Tcherepanova. Biochim Biophys Acta. 2005 Jun 20;1724 (1-2):127-36
Dendritic cell subsets generated from CD34(+) hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses.
Hideki Ueno, Irina Tcherepanova, Olivier Reygrobellet, Erik Laughner, Claire Ventura, A Karolina Palucka, Jacques Banchereau. J Immunol Methods. 2004 Feb 15;285 (2):171-80
Posters and Presentations
Development of a cellular immunotherapy for ART naďve patients for the purpose of delaying or preventing initiation of ART therapy.
I.Y. Tcherepanova, D.M. Calderhead, M.A. DeBenedette, R.Jain, J.P. Routy, C.A. Nicolette HIV DART (2010), Los Cabos, Mexico.
Mature Dendritic Cells Electroporated with CD40L RNA Produce IL-12 a Critical Component of Dendritic Cell Based Immune-Therapy Necessary for the Induction of Multi-Functional Effector/Memory CD8+/CD28+ CTL.
M. DeBenedette, D. Calderhead, I. Tcherepanova, C. Nicolette and D. Healey. Keystone Symposia - Immunological Mechanisms of Vaccination (S1) (2010) Seattle, WA USA
Cancer Immunotherapy: A long Awaited reality.
October 21, 2010 New York Academy of Medicine New York City. AN EXCLUSIVE CONFERENCE EVENT & TELEVISED SERIES. Fred Miesowicz and Charles Nicolette presentation.
Webinar with leading researchers in renal cell carcinoma (RCC) to discuss novel therapies, recently approved or in development, as well as the promise of personalized immunotherapy in the treatment of RCC.
November 1, 2010 (Webinar link)
The Argos Approach to Personalized Dendritic Cell Immunotherapies.
F. Miesowicz. ISPE Fall Annual Gala for the local CASA chapter in Cary, NC USA ( 2010)
Assessing & Implementing Automation session/panel discussion.
F. Miesowicz. Cell Therapy Industry Summit hosted by Invitrogen Carlsbad, CA Nov 2010
Process Development and Clinical Manufacturing for Autologous Dendritic Cell Immunotherapies.
T. Monesmith. BioProcess International Conference and Convention Providence RI USA (Sep 2010)
Encouraging progression free survival results in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) participating in a phase II study testing the safety and activity of a dendritic cell-based immunotherapeutic (AGS-003) in combination with sunitinib
RA Figlin, A Amin, AZ Dudek, T Logan, RS Lance, JM Holzbeierlein, WL Williams, RG Jain, T. Monesmith, I. Tcherepanova, F Miesowicz, CA Nicolette, AGS-003-006 Study Group. Ninth International Kidney Cancer Symposium Chicago, IL USA (2010)
An autologous AI approach to treating HIV infection.
CA Nicolette, IY Tcherepanova, D Healey, D Calderhead, M DeBenedette, R Jain, WL Williams, T Monesmith, F Miesowicz, JP Routy, J Jacobson, AGS-004-001 Study Group. Active Immunotherapeutics forum, Barcelona, Spain (2010)
A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib
A Amin, AZ Dudek, T Logan, RS Lance, JM Holzbeierlein, WL Williams, RG Jain, IY Tcherepanova, CA Nicolette, TT Monesmith, RA Figlin, AGS-003-006 Study Group. ASCO 2010 Annual Meeting (2010) Chicago, IL USA
Evaluation of the Agilent Bioanalyzer 2100 for quality determination of IVT RNA.
JG Slagter-Jäger, C Nicolette and I Tcherepanova. 15th Annual Meeting of RNA society, Seattle WA, USA (2010).
Immunologic activity of a fully autologous dendritic cell immunotherapy for the treatment of HIV-1 infected subjects.
D Healey, B Yassine-Diab, Z Coutsinos, C Landry, D Gagnon, C Hebert-Benoit, R Boulassel, JP Routy, S Vezina, C Tremblay, M Loutfy, F Smaill, J Gill, JG Baril, R Jain, I Tcherepanova, and RP Sekaly, CA Nicolette. XVIII International AIDS Conference, Vienna, Austria (2010).
HIV-1 infected subjects treated with an autologous dendritic cell therapy (AGS-004), exhibited a significant reduction in viral load (when compared to pre-ART viral load) and delay in the time to viral rebound during a 12 week AGS 004-001 Study Group.
J.-P. Routy, J. Angel, S. Vezina, C. Tremblay, M. Loutfy, J. Gill, J.-G. Baril, F. Smaill, R. Jain, R. Boulassel, C. Nicolette. STI. XVIII International AIDS Conference, Vienna, Austria (2010).
AGS-004, an autologous dendritic cell therapy impacts on the evolution of residual HIV virus along with a substantial increase in time to viral rebound, during an STI in the CTN 239 clinical study
Tcherepanova I, Boulassel MR, Carreno A, Carpenter H, Loutfy MR, Vezina S, Tremblay C, Angel, J, Gill J, Baril, J, Smaill F, Jain R, Healey D, Chew T , Nicolette C. and Routy JP. 19th Annual Canadian Conference on HIV/AIDS Research, Saskatoon, Canada (2010).
Study of rebound virus genetic diversity in subjects treated with autologous DC based (AGS-004) immunotherapy after ART interruption.
I.Y. Tcherepanova, A.D. Carreńo, J.H. Carpenter, J. Harris, J.P. Routy, R. Jain, D. Healey, T. Chew and C.A. Nicolette. Keystone Symposium: HIV Vaccines. Banff, Canada (2010)
Challenges of Manufacturing Autologous Cell Therapies.
T. Monesmith NC State ISPE student chapter Raleigh NC, USA (2010)
Immunogenicity of an autologous dendritic cell anti-HIV therapy in HIV-1 infected individuals.
AIDS Vaccine Conference, October 19-22 2009. Paris, France
Yassine DB, Coustinos Z, Landry C, Gagnon D, Sauve D, Herbert-Benoit C, Hebert V, Levesque G, Kay P, Bounif N, Boulassel M, Routy J, Jain R, Tcherepanova I, Healey D, Nicolette C and Sekaly R. Poster presentation
Safety and Viral load changes in HIV-1 infected subjects treated with autologous dendritic immune therapy following ART discontinuation.
Routy J, Boulassel M, Loutfy M, Vezina S, Tremblay C, Angel J, Gill J, Baril J, Smaill F, Jain R, Healey D, Tcherepanova I, Nicolette C and Sekaly R. Oral Presentation
Assessing risk of a 12- week antiretroviral therapy discontinuation as a read out of viral control in immune-based therapy (AGS-004-001).
5th International IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 19-22 2009 Cape Town, South Africa
Routy J, Jain R, Boulassel M, Nicolette C, Finke L and Jacobson J. Poster No MOPEB092.
Safety and feasibility of a multicentre phase 2 trial using autologous dendritic cell (DC) therapy to control viral replication following ART discontinuation (CTN#239).
Canadian Association of HIV Researchers, Vancouver, April 23-25th 2009
Routy J, Vezina S, Tremblay C, Baril J, Loutfy M, Gill J, Jain R, Nicolette C, Sekaly R and Boulassel MR for the CTN 239 investigators
A Nursing Perspective of Apheresis Procedures Performed in HIV-Infected Subjects Receiving a Monocytes-Derived Dendritic Cell-Based Immunotherapy.
D Feng , C Goupil , J Mathieu , M. Delisle, S Girard , C Landry , C Gagné , M Swidzinski, MR Boulassel , JP Routy for the CTN-239 Study Investigators
The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90.
Keystone HIV Immunobiology 2009
Irina Tcherepanova, Aijing Starr, Melissa Adams. Brad Lackford, David Calderhead, Don Healey, Mohamed-Rachid Boulassel, Jean-Pierre Routy and Charles Nicolette
Soluble CD83 promotes tolerance induction to minor mismatched skin transplants and allogeneic heart transplants in the mouse.
10th International Symposium on Dendritic Cells, 2009
Elisabeth Zinser, Hao Wang, Stephen Brand, Charles Nicolette, Robert Zhong, William J. Wall and Alexander Steinkasserer
Soluble CD83 Mediated Suppression of B-cell Activation and Differentiation Prolongs Murine Cardiac Allograft Survival.
American Society of Transplantation Congress 2009
Wei Ge, Siobhan I. Ramcharran, Jacqueline Arp, Miren L. Baroja, Zhu Lan, Jifu Jiang, Weihua Liu, Anthony Jevnikar, Stephen Brand, Charles Nicolette, Bertha Garcia, and Hao Wang
Modulation of Dendritic Cells by Soluble CD83 Induces Kidney Allograft Tolerance.
Zhu Lan, Wei Ge, Miren L. Baroja, Jacqueline Arp, Jifu Jiang, Weihua Liu, Stephen Brand, Charles Nicolette, Bertha Garcia, and Hao Wang
Soluble CD83: Its Safety and Efficacy in a Non-Human Primate Kidney Allotransplantation Model.
M L Baroja, Z Lan, J Arp, Weihua LiuG,Strejan, S Brand, C Nicolette, W Wall, B Garcia, D M Rothstein, A M Jevnikar, and H Wang
The Soluble Extracellular Domain of CD83 is Capable of Generating Regulatory T Cells in Non-Human Primates.
American Society of Transplantation Congress 2008
Miren Baroja, Jacqueline Arp, Siobhan Ramcharan, Stephen Brand, Anthony M. Jevnikar, Gill Strejan, William Wall, and Hao Wang
An automated approach for manufacturing personalized dendritic cell immunotherapies.
ISCT 14th Annual Meeting 2008
Monesmith T., Williams L., Martin B., Peel T., Kneen D., Spence S., Grant R., Miesowicz F.
Autologous dendritic cell immunotherapeurtic (Arcellis™ for HIV): tolerability and immunogenicity in HIV-1 infected subjects treated with ART.
XVII International AIDS Conference 2008
Routy, JP, Yassine-Diab, B, Laundry, C, Yegorov, O, Boulassel MR, Benoit-Hebert, C. Antar, R., Tcherepanova, I., Healey, D., Jain R., Finke L, Nicolette, C., Sekaly RP.
A Phase I safety and feasibility study of autologous dendritic cell therapy in ART treated HIV infected subjects (CAN-HIV-001)
Keystone HIV Vaccine 2008
JP Routy, NR Boulassel, C Laundry, B Yassine-Diab, R Antar, I Tcherepanova, D Healey, F Miesowicz, C Nicolette, LH Finke, RP Sekaly.
Post transcriptionally capped HIV RNAs confer higher antigen expression level in DCs.
I. Tcherepanova, A. Starr, A. Raney, D. Calderhead, J. Horvatinovich, D. Healey, C. Nicolette
IL-12 as an immunopotency marker for fully autologous dendritic cell immunotherapeutics.
23rd Annual Meeting of ISBTC 2008
Don Healey, David Calderhead, Alicia Gamble, Joe Horvatinovich, Helen Ketterningham, Irina Tcherepanova, Charles Nicolette and Mark DeBenedette
The Soluble Extracellular Domain of CD83 is Capable of Generating Regulatory T Cells in Non-Human Primates.
American Society of Transplantation Congress 2008
Miren Baroja, Jacqueline Arp, Siobhan Ramcharan, Stephen Brand, Anthony M. Jevnikar, Gill Strejan, William Wall, and Hao Wang
Soluble CD83 mediated B cell suppression prolongs murine allograft survival
American Society of Transplantation Congress 2007
Siobhan Ramcharan, Jacqueline Arp, Miren Baroja Stephen Brand, Gill Strejan, Hao Wang, Anthony M. Jevnikar, and Robert Zhong
Immunosuppressive properties of soluble extracellular domain of CD83 on antigen-presenting cells of cynomologous monkey
Miren Baroja, Jacqueline Arp, Siobhan Ramcharan, Stephen Brand, Anthony M. Jevnikar, Gill Strejan, Hao Wang, William Wall, and Robert Zhong
Targeting a novel immunomodulatory protein by soluble CD83 promote tolerance induction in a mouse cardiac transplantation model
Hao Wang, Wei Ge, Weihua Liu, Dameng Lian, Miren Baroja, Siobhan Ramcharan, Bertha Garcia, Robert Zhong, William Wall
PME CD40L DC prime the expansion of CD28+/CD45RA- long lived effector memory CTL having clinical relevance fo dendritic cell based immunotherapies
22nd Annual Meeting of ISBTC 2007
Don Healey, David Calderhead, Alicia Gamble, Joe Horvatinovich, Helen Ketterningham, Irina Tcherepanova, Charles Nicolette, Mark DeBenedette
Sorafenib but not Sunitinib inhibits human T-cell function in vitro: Implications for combined TKI and Immunotherapy strategies for the treatment of cancer.
Don Healey, David Calderhead, Alicia Gamble, Helen Ketteringham, Robert Figlin, Harry Drabkin, Lothar Finke, Charles Nicolette, Mark DeBenedette
Post-maturation dendritic cells electroporated with CD154 RNA (PME-CD154 DC) prime the expansion of high avidity self-reactive CTL
Mark DeBenedette, David Calderhead, Alicia Gamble, Joe Horvatinovich, Helen Ketteringham, Melissa Adams, Brad Lackford, Irina Tcherepanova, Charles Nicolette and Don Healey
Novel customized DC based immunotherapy tailored to the infecting patient’s HIV: from conception to clinic.
9th International Conference Drug and Gene Based Therapeutics Crete Greece 2006
I. Tcherepanova
Autologous Nef RNA HIV-1 Electroporated DC enhances the detection of CD8-cpecific proliferative responses.
13th Annual Meeting CROI 2006 (Denver)
Oleg Yegorov, Bader Yassine-Diab,Tom Baumgartner, Rachid Boulassel , Jean-Pierre Routy, Don Healey, Irina Tcherepanova, Charles Nicolette and Rafick-Pierre Sekaly
Optimization of autologous RNA transfected DC therapy product
Keystone HIV Vaccine 2006
Irina Tcherepanova, Brad Lackford, Jason Harris, Don Healey, Joe Horvatinovich, Charles Nicolette
Development of CD4 independent primary CD8 CTL activity in vitro by co-transfection of RNAs encoding antigen and CD40L into pre-matured DC
9th International Conference on Dendritic Cells 2006
Don Healey, Mark DeBenedette, Alicia Gamble, Joe Horvatinovich, Helen Ketteringham, Melissa Adams, Brad Lackford, Irina Tcherepanova, Charles Nicolette and David Calderhead
Novel Method of DC Maturation: Intracellular Ligation of CD40 by a truncated CD154 encoded by RNA.
21st Annual Meeting of ISBT 2006
I Tcherepanova., Adams M., Hinohara A., Horvatinovich., J., Healey D., Nicolette C., J. Immunotherapy, Abstracts of 21st annual meeting of ISBT V 29 n6 2006 p670.
Development of CD4 independent primary CD8 CTL activity in vitro by co-transfection of RNAs encoding antigen and CD40L into prematured DC
Keystone Symposium 2007: “Immunological Intervention in Human Disease”
David Calderhead, Mark DeBenedette, Alicia Gamble, Joe Horvatinovich, Helen Ketteringham, Melissa Adams, Brad Lackford, Irina Tcherepanova, Charles Nicolette and Don Healey
Autologous RNA transfected dendritic cell based anti HIV vaccine.
Keystone HIV Vaccine 2005
I. Tcherepanova., Harris J., Lackford B., Calderhead D.
Autologous HIV electroporated DC enhances the detection of CD8 specific proliferative responses.
AIDS Vaccine 2005 (Montreal)
O. Yegorov, Yassine Diab B., Chambenoit O., Gangon B., Boulassel R., Routy JP., Heley D., Harris J., Tcherepanova I., Nicolette C., Sekaly RP.
A novel strain-independent anti HIV vaccine targets autologous virus and its quasispecies.
AIDS Vaccine 2005 (Montreal)
Tcherepanova I., Harris J., Lackford B., Yassine Diab., B., Yegorov O., Sekaly RP., Nicolette C.
Development of CD4+ independent CD8+ CTL activity in vitro by transfection of CD154 (CD40 ligand) mRNA into dendritic cells
Keystone Symposium 2005: “Dendritic Cells at the Center of Innate and Adaptive Immunity: Eradication of Pathogens and Cancer and Control of Immunopathology”
David Calderhead, Alicia Hedgepeth, Helen Ketteringham, Joe Horvatinovich, Charles Nicolette and Don Healey
Flu-MP RNA-transfected subsets of CD34-HPCs derived DCs induce potent recall immune responses.
Keystone 2004
Hideki Ueno, Irina Tcherepanova, Olivier Reygrobellet, Claire Ventura, A. Karolina Palucka and Jacques Banchereau. Baylor Institute for Immunology Research Dallas, TX and Merix Bioscience, Inc
|
|
 |
|
